Nova Eye Medical (EYE) Discussion, page-18

NEU just received approval for Trofinetide, the first ever treatment for Rett Syndrome (a rare disease that affects far fewer people than iAMD does).

This stock was also at 30c at one point, today it will likely go above $10 (there are a similar number of shares to EYE). Just goes to show how being first to treat a significant disease can result in huge gains for those that are patient.

For us, not only do we have 2RT as the first ever treatment for iAMD (a common and extremely debilitating disease affecting 1 in 7 people compared to 1 in 15,000 for Rett Syndrome), but we also have iTrack (which has been available since 2008) and iTrack Advance, (being launched in the next few weeks), which will deliver strong revenue and hopefully soon cash flow to the company between now and the commercialisation of 2RT.

The best bit though is at the moment, the market capitalisation for EYE is so low that it is failing to account for 2RT (it is only valuing iTrack and iTrack Advance). I expect that the partnership we are seeking will give 2RT an equity valuation, which should result in a re-rate of EYE's share price. In the meantime, we are essentially getting a free option to benefit from 2RT success, without any of the risk (given it is not being accounted for in the valuation)

Obviously one is a drug and another is a medical device so they are different, but revenues should be similarly recurring due to the pay-per-use structure and the dynamics are similar in that they too sought a partnership to get them through clinical trials and to commercialisation.

Also, happy World Glaucoma Week to all EYE shareholders!!! This would be a very fitting week to get FDA clearance for iTrack Advance